BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc., a leading company in radiopharmaceuticals, has announced the upcoming presentation of new data at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in New Orleans, LA, from June 21-24, 2025. The presentations will highlight two oncology radiodiagnostic agents. Notably, the session titled "First Clinical Evaluation of 68Ga-LNTH-1363S, a Novel FAP-Targeting Radiopharmaceutical for PET Imaging," will be presented by Ida Sonni from the University of California, Los Angeles, on June 23, 2025. Additionally, Gyu Seong Heo from Washington University will present on the preclinical assessment of 64Cu-LNTH-1363S for FAP PET imaging in cardiovascular applications on June 24, 2025. The findings will be shared with the medical community during these sessions, contributing to advancements in radiopharmaceutical applications in oncology and cardiovascular imaging.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。